A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT05736419 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease
Thalassemia, Beta
Thalassemia

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Tacrolimus
DRUG: Mycophenolate Mofetil
BIOLOGICAL: Rabbit ATG
DRUG: Dexamethasone
DRUG: Bortezomib
DRUG: Rituximab

Sponsor

Memorial Sloan Kettering Cancer Center